About Sudarshan Pharma Industries Limited
Data last updated: 21 December 2025
Sudarshan Pharma Industries Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in scientific services, a part of the broader professional services sector. Incorporated on 23 July 2008, the company has been in operation for over 18 years.
Registered with ROC Mumbai under CIN L51496MH2008PLC184997. Listed.
Capital: an authorised share capital of ₹35 Cr and a paid-up capital of ₹24.07 Cr. Formerly known as Sudarshan Pharma Industries Private Limited and Sudarshan Speciality Chemsolve Private Limited. It is led by directors including Jaya Ankur Singhania and Vijay Ojha.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: 301 3Rd Floor Aura Biplex Above Kalyan Jewellers S. V. Road Borivali (West), Mumbai, Maharashtra, India – 400092.
As per the financials filed for FY 2025, the company reported a revenue of ₹507.57 Cr, a growth of 9% compared to the previous year.
The company has a workforce of approximately 9 employees as per the latest available data. Its group structure includes 3 subsidiaries.
The company is associated with 2 brands - Farm2energy, Sudarshan Pharma. As per MCA filings, the company has open charges of ₹254.91 Cr and satisfied charges of ₹24.85 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sudarshanpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address301 3Rd Floor Aura Biplex Above Kalyan Jewellers S. V. Road Borivali (West), Mumbai, Maharashtra, India – 400092
-
IndustryProfessional Services, Scientific, Technical, Personal
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited has undergone 2 name changes throughout its history. The company was previously known as Sudarshan Pharma Industries Private Limited, and Sudarshan Speciality Chemsolve Private Limited. The current legal name is Sudarshan Pharma Industries Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Sudarshan Pharma Industries Limited | Current |
| Sudarshan Pharma Industries Private Limited | Previous |
| Sudarshan Speciality Chemsolve Private Limited | Previous |
CIN History of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L51496MH2008PLC184997, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L51496MH2008PLC184997 | Current |
| U51496MH2008PTC184997 | Previous |
| U51496MH2008PLC184997 | Previous |
Associated Brands with Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited operates two associated brands: Farm2energy and Sudarshan Pharma. These brands represent Sudarshan Pharma Industries Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Offers online slot gaming with jackpots and integrated e-commerce features for users. | farm2energy.com | |
| Sudarshan Pharma is engaged in manufacturing pharmaceuticals and specialty chemicals. | sudarshanpharma.com |
Competitors & Alternatives of Sudarshan Pharma Industries Limited
Brands and companies operating in the same space as Sudarshan Pharma Industries Limited include Carbo Culture, Vgrid Energy Systems, Kapsera and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Carbo Culture
|
Producer and supplier of biochar | Woodside, United States, United States | 2016 |
Vgrid Energy Systems
|
Compact biomass energy units are generated from farm waste. | Camarillo, United States, United States | 2013 |
Kapsera
|
Biodegradable microfluidic encapsulation technology is developed for agricultural inputs. | Paris, France, France | 2018 |
Takachar
|
Portable biomass upcycling equipment is developed for rural residue processing. | Cambridge, United States, United States | 2018 |
Fibsol
|
Eco-friendly products for agriculture and healthcare are provided using nanofibers. | Chennai, India, India | 2013 |
Plant Impact
|
Biostimulant products are developed to enhance crop yield and quality. | Harpenden, United Kingdom, United Kingdom | 2006 |
Cool Planet
|
Biomass is converted into green fuels and biocarbon products. | Camarillo, United States, United States | 2009 |
Zero Gravity Solutions
|
Nutrient solutions and plant varieties are developed and offered. | Boca Raton, United States, United States | 1983 |
Business Activity of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited is engaged in principal business activities including trade and professional, scientific and technical, with detailed activities including wholesale trading, other professional, scientific and technical activities. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities | ********* |
Auditor Details of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited is audited by NGST & Associates (ICAI peer reviewed, certificate valid till 2027-08-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| NGST & Associates (ICAI peer reviewed, certificate valid till 2027-08-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited is currently managed by 9 directors, with 21 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Jaya Ankur Singhania
Also directs:
Avabodha Bharat Legal Advisory & Training Llp, J S Singhania And Co. Llp, Jet Freight Logistics Limited and 5 more
|
Director | 27 Dec 2022 | 3 Years 6 Months | Current |
| Vijay Ojha | Additional Director | 18 Oct 2025 | 0 Years 8 Months | Current |
|
Rushabh Prashant Patil
Also directs:
Jet Freight Logistics Limited, Nandana Metals And Mining Limited
|
Director | 21 Jul 2023 | 2 Years 11 Months | Current |
|
Hemal Vasantrai Mehta
Also directs:
Sudarshan Akshar Speciality Chemicals Llp, Life Science Chemical Private Limited, Sudarshan Maven Pharma Private Limited and 5 more
|
Managing Director | 16 Jan 2015 | 11 Years 5 Months | Current |
|
Sachin Vasantrai Mehta
Also directs:
Life Science Chemical Private Limited, Sudarshan Maven Pharma Private Limited, Ratna Lifesciences Private Limited and 5 more
|
Managing Director | 23 Jul 2008 | 17 Years 11 Months | Current |
| Nirav Kishor Shah | Company Secretary | 01 Jun 2024 | 2 Years 1 Months | Current |
Financials of Sudarshan Pharma Industries Limited FY 2026 filings available
Sudarshan Pharma Industries Limited reported revenue of ₹703.06 Cr (up 39.21% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹703.06 Cr | ₹505.05 Cr | ₹463.54 Cr | ₹461.33 Cr |
| Other Income | ₹8.71 Cr | ₹2.52 Cr | ₹2.61 Cr | ₹1.12 Cr |
| Total Income | ₹711.77 Cr | ₹507.57 Cr | - | - |
| Cost of Materials Consumed | ₹39.06 Cr | ₹8.93 Cr | ₹6.31 Cr | ₹32.27 Lakh |
| Purchases of Stock-in-Trade | ₹652.13 Cr | ₹485.18 Cr | ₹424.04 Cr | ₹457.25 Cr |
| Changes in Inventories | -₹71.81 Cr | -₹54.35 Cr | -₹7.87 Cr | -₹26.62 Cr |
| Employee Benefit Expense | ₹7.44 Cr | ₹4.89 Cr | ₹3.64 Cr | ₹2.98 Cr |
| Finance Costs | ₹25.7 Cr | ₹15.77 Cr | ₹8.94 Cr | ₹5.4 Cr |
| Depreciation & Amortisation | ₹3.79 Cr | - | - | - |
| Other Expenses | ₹24.93 Cr | ₹20.48 Cr | ₹14.61 Cr | ₹12.72 Cr |
| Total Expenses | ₹681.23 Cr | ₹483.12 Cr | ₹450.92 Cr | ₹452.95 Cr |
| Profit Before Exceptional Items & Tax | ₹30.54 Cr | - | - | - |
| Exceptional Items | ₹0 | - | - | - |
| Profit Before Tax | ₹30.54 Cr | ₹21.63 Cr | ₹15.23 Cr | ₹9.5 Cr |
| Total Tax Expense | ₹7.17 Cr | ₹5.75 Cr | ₹3.77 Cr | ₹2.46 Cr |
| Net Profit | ₹23.37 Cr | ₹15.88 Cr | ₹11.46 Cr | ₹7.04 Cr |
| attributable to Owners | ₹23.3 Cr | - | - | - |
| attributable to NCI | ₹6.84 Lakh | - | - | - |
| Other Comprehensive Income | ₹5.05 Lakh | - | - | - |
| Total Comprehensive Income | ₹23.42 Cr | - | - | - |
| EBITDA (computed) | ₹60.03 Cr | - | - | - |
| Basic EPS | ₹0.97 | - | - | - |
| Diluted EPS | ₹0.97 | - | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹641.75 Cr | ₹402.41 Cr | ₹283.13 Cr | ₹232.48 Cr |
| Non-current Assets | ₹151.48 Cr | ₹67.56 Cr | ₹41.55 Cr | ₹33.86 Cr |
| Current Assets | ₹490.26 Cr | ₹334.85 Cr | ₹241.57 Cr | ₹198.62 Cr |
| Property, Plant & Equipment | ₹77.41 Cr | ₹20.05 Cr | - | - |
| Inventories | ₹218.74 Cr | ₹140.48 Cr | ₹85.74 Cr | ₹74.57 Cr |
| Trade Receivables | ₹233.34 Cr | - | - | - |
| Cash & Equivalents | ₹1.13 Cr | ₹6.28 Lakh | ₹14.35 Lakh | ₹11.72 Cr |
| Equity (Net Worth) | ₹156.32 Cr | - | - | - |
| Equity Share Capital | ₹24.07 Cr | - | - | - |
| Borrowings (Non-current) | ₹28.37 Cr | - | - | - |
| Borrowings (Current) | ₹255.11 Cr | - | - | - |
| Total Debt (computed) | ₹283.47 Cr | - | - | - |
| Current Liabilities | ₹456.12 Cr | ₹259.74 Cr | ₹160.82 Cr | ₹118.48 Cr |
| Total Liabilities | ₹485.43 Cr | - | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | -₹2.3 Cr | -₹26.09 Cr | -₹73.26 Cr | -₹24.46 Cr |
| Investing Cash Flow | -₹77.7 Cr | -₹20.41 Cr | ₹5.24 Cr | -₹26.33 Cr |
| Financing Cash Flow | ₹80.58 Cr | ₹46.87 Cr | ₹56.44 Cr | ₹62.27 Cr |
| Capital Expenditure | ₹69.1 Cr | ₹58.57 Lakh | - | - |
| Free Cash Flow (computed) | -₹71.4 Cr | -₹26.68 Cr | - | - |
| Dividends Paid | ₹0 | ₹0 | ₹72.2 Lakh | ₹0 |
| Net Change in Cash | ₹58.43 Lakh | ₹36.86 Lakh | -₹11.57 Cr | ₹11.48 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|---|
| Revenue from Operations | ₹220.92 Cr | ₹168.01 Cr | ₹168.87 Cr | ₹145.26 Cr |
| Other Income | ₹4.13 Cr | ₹1.52 Cr | ₹1.86 Cr | ₹1.21 Cr |
| Total Income | ₹225.05 Cr | ₹169.52 Cr | ₹170.73 Cr | ₹146.47 Cr |
| Cost of Materials Consumed | ₹20.12 Cr | ₹13.21 Cr | ₹30.95 Lakh | ₹5.42 Cr |
| Purchases of Stock-in-Trade | ₹192.61 Cr | ₹148.81 Cr | ₹171.18 Cr | ₹139.53 Cr |
| Changes in Inventories | -₹22.68 Cr | -₹14.22 Cr | -₹19.17 Cr | -₹15.73 Cr |
| Employee Benefit Expense | ₹2.1 Cr | ₹1.97 Cr | ₹1.78 Cr | ₹1.58 Cr |
| Finance Costs | ₹7.53 Cr | ₹6.28 Cr | ₹5.94 Cr | ₹5.96 Cr |
| Depreciation & Amortisation | ₹1.09 Cr | ₹91.1 Lakh | ₹90.12 Lakh | ₹88.35 Lakh |
| Other Expenses | ₹8.57 Cr | ₹7.36 Cr | ₹5.57 Cr | ₹3.42 Cr |
| Total Expenses | ₹209.34 Cr | ₹164.33 Cr | ₹166.5 Cr | ₹141.06 Cr |
| Profit Before Exceptional Items & Tax | ₹15.7 Cr | ₹5.2 Cr | ₹4.23 Cr | ₹5.41 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹15.7 Cr | ₹5.2 Cr | ₹4.23 Cr | ₹5.41 Cr |
| Total Tax Expense | ₹4.31 Cr | ₹1.05 Cr | ₹35.55 Lakh | ₹1.45 Cr |
| Net Profit | ₹11.39 Cr | ₹4.15 Cr | ₹3.87 Cr | ₹3.96 Cr |
| attributable to Owners | ₹10.73 Cr | ₹4.36 Cr | ₹4.18 Cr | ₹4.03 Cr |
| attributable to NCI | ₹66.62 Lakh | -₹20.87 Lakh | -₹31.09 Lakh | -₹7.82 Lakh |
| Other Comprehensive Income | ₹7.37 Lakh | -₹89,000 | -₹89,000 | -₹89,000 |
| Total Comprehensive Income | ₹11.47 Cr | ₹4.14 Cr | ₹3.86 Cr | ₹3.95 Cr |
| EBITDA (computed) | ₹24.32 Cr | ₹12.39 Cr | ₹11.07 Cr | ₹12.25 Cr |
| Basic EPS | ₹0.48 | ₹0.18 | ₹0.16 | ₹0.16 |
| Diluted EPS | ₹0.47 | ₹0.18 | ₹0.16 | ₹0.16 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹667.5 Cr | ₹502.51 Cr | ₹465.56 Cr | ₹461.33 Cr |
| Other Income | ₹8.4 Cr | ₹2.88 Cr | ₹2.75 Cr | ₹1.12 Cr |
| Total Income | ₹675.9 Cr | ₹505.38 Cr | - | - |
| Cost of Materials Consumed | ₹2.98 Cr | ₹4 Cr | ₹4.82 Cr | ₹32.27 Lakh |
| Purchases of Stock-in-Trade | ₹655.99 Cr | ₹488.59 Cr | ₹427.58 Cr | ₹457.25 Cr |
| Changes in Inventories | -₹70.63 Cr | -₹53.3 Cr | -₹7.87 Cr | -₹26.62 Cr |
| Employee Benefit Expense | ₹6.19 Cr | ₹4.56 Cr | ₹3.5 Cr | ₹2.98 Cr |
| Finance Costs | ₹25.3 Cr | ₹15.96 Cr | ₹9.03 Cr | ₹5.4 Cr |
| Depreciation & Amortisation | ₹3.41 Cr | - | - | - |
| Other Expenses | ₹24.01 Cr | ₹20.15 Cr | ₹14.93 Cr | ₹12.72 Cr |
| Total Expenses | ₹647.23 Cr | ₹481.28 Cr | ₹453.22 Cr | ₹452.95 Cr |
| Profit Before Exceptional Items & Tax | ₹28.67 Cr | - | - | - |
| Exceptional Items | ₹0 | - | - | - |
| Profit Before Tax | ₹28.67 Cr | ₹21.29 Cr | ₹15.1 Cr | ₹9.5 Cr |
| Total Tax Expense | ₹6.69 Cr | ₹5.41 Cr | ₹3.74 Cr | ₹2.46 Cr |
| Net Profit | ₹21.98 Cr | ₹15.88 Cr | ₹11.36 Cr | ₹7.04 Cr |
| Other Comprehensive Income | ₹1.53 Lakh | - | - | - |
| Total Comprehensive Income | ₹22 Cr | - | - | - |
| EBITDA (computed) | ₹57.37 Cr | - | - | - |
| Basic EPS | ₹0.91 | - | - | - |
| Diluted EPS | ₹0.90 | - | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹594.18 Cr | ₹400.4 Cr | ₹284.84 Cr | ₹232.47 Cr |
| Non-current Assets | ₹149.43 Cr | ₹66.57 Cr | ₹39.64 Cr | ₹33.96 Cr |
| Current Assets | ₹444.75 Cr | ₹333.83 Cr | ₹245.2 Cr | ₹198.51 Cr |
| Property, Plant & Equipment | ₹72.77 Cr | ₹19.46 Cr | - | - |
| Inventories | ₹206.66 Cr | ₹137.04 Cr | ₹84.37 Cr | ₹74.57 Cr |
| Trade Receivables | ₹199.23 Cr | - | - | - |
| Cash & Equivalents | ₹10.9 Lakh | ₹6.28 Lakh | ₹13.12 Lakh | ₹11.71 Cr |
| Equity (Net Worth) | ₹152.71 Cr | - | - | - |
| Equity Share Capital | ₹24.07 Cr | - | - | - |
| Borrowings (Non-current) | ₹30.39 Cr | - | - | - |
| Borrowings (Current) | ₹250.7 Cr | - | - | - |
| Total Debt (computed) | ₹281.09 Cr | - | - | - |
| Current Liabilities | ₹410.05 Cr | ₹257.98 Cr | ₹162.61 Cr | ₹118.46 Cr |
| Total Liabilities | ₹441.47 Cr | - | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | -₹2.75 Cr | -₹27.85 Cr | -₹73.38 Cr | -₹24.45 Cr |
| Investing Cash Flow | -₹79.71 Cr | -₹20.24 Cr | -₹1.25 Cr | -₹26.33 Cr |
| Financing Cash Flow | ₹82.18 Cr | ₹48.35 Cr | ₹63.05 Cr | ₹62.27 Cr |
| Capital Expenditure | ₹49.99 Cr | ₹53.19 Lakh | - | - |
| Free Cash Flow (computed) | -₹52.74 Cr | -₹28.39 Cr | - | - |
| Dividends Paid | ₹0 | ₹0 | ₹72.2 Lakh | ₹0 |
| Net Change in Cash | -₹27.96 Lakh | ₹25.74 Lakh | -₹11.58 Cr | ₹11.48 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|---|
| Revenue from Operations | ₹199.81 Cr | ₹158.37 Cr | ₹167.01 Cr | ₹142.31 Cr |
| Other Income | ₹3.21 Cr | ₹1.69 Cr | ₹2.09 Cr | ₹1.41 Cr |
| Total Income | ₹203.02 Cr | ₹160.06 Cr | ₹169.1 Cr | ₹143.73 Cr |
| Cost of Materials Consumed | ₹1.06 Cr | ₹58.15 Lakh | ₹65.93 Lakh | ₹67.94 Lakh |
| Purchases of Stock-in-Trade | ₹193.57 Cr | ₹151.78 Cr | ₹171.76 Cr | ₹138.89 Cr |
| Changes in Inventories | -₹23.29 Cr | -₹13.65 Cr | -₹21.57 Cr | -₹12.12 Cr |
| Employee Benefit Expense | ₹1.85 Cr | ₹1.68 Cr | ₹1.4 Cr | ₹1.26 Cr |
| Finance Costs | ₹7.27 Cr | ₹6.24 Cr | ₹6.07 Cr | ₹5.71 Cr |
| Depreciation & Amortisation | ₹1 Cr | ₹80.63 Lakh | ₹80.68 Lakh | ₹78.98 Lakh |
| Other Expenses | ₹8.32 Cr | ₹7.21 Cr | ₹5.15 Cr | ₹3.33 Cr |
| Total Expenses | ₹189.78 Cr | ₹154.65 Cr | ₹164.27 Cr | ₹138.53 Cr |
| Profit Before Exceptional Items & Tax | ₹13.23 Cr | ₹5.42 Cr | ₹4.83 Cr | ₹5.19 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹13.23 Cr | ₹5.42 Cr | ₹4.83 Cr | ₹5.19 Cr |
| Total Tax Expense | ₹3.69 Cr | ₹1.11 Cr | ₹42.47 Lakh | ₹1.46 Cr |
| Net Profit | ₹9.54 Cr | ₹4.31 Cr | ₹4.4 Cr | ₹3.73 Cr |
| Other Comprehensive Income | ₹4.14 Lakh | -₹87,000 | -₹87,000 | -₹87,000 |
| Total Comprehensive Income | ₹9.58 Cr | ₹4.3 Cr | ₹4.39 Cr | ₹3.72 Cr |
| EBITDA (computed) | ₹21.51 Cr | ₹12.46 Cr | ₹11.7 Cr | ₹11.7 Cr |
| Basic EPS | ₹0.40 | ₹0.18 | ₹0.18 | ₹0.15 |
| Diluted EPS | ₹0.39 | ₹0.18 | ₹0.18 | ₹0.15 |
Shareholding Pattern of Sudarshan Pharma Industries Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 57.39%, foreign institutional investors hold 19.95%, retail and other public shareholders hold 22.61% of Sudarshan Pharma Industries Limited. The company had 1,346 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 57.39% | 57.39% | 57.39% | 57.39% | 57.39% | 57.39% |
| Public | 42.61% | 42.61% | 42.61% | 42.61% | 42.61% | 42.61% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Promoters | 57.39% | 57.39% | 57.39% | 52.47% |
| Public | 42.61% | 42.61% | 42.61% | 47.53% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | +4.92 | - |
Group Structure of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited has 3 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Sudarshan Pharma Industries Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Life Science Chemical Private Limited | U21001GJ2023PTC144108 | - |
| Sudarshan Pharma Lifescience Private Limited | U24299MH2021PTC357350 | - |
| Ratna Lifesciences Private Limited | U74999PN2017PTC168995 | - |
Showing major subsidiaries. Total: 3.
Charges & Borrowings of Sudarshan Pharma Industries Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 May 2025 | Indian Bank | ₹30 Cr | Open |
| 26 Dec 2024 | Others | ₹48 Cr | Open |
| 21 Nov 2024 | Others | ₹3.03 Cr | Open |
| 29 Jul 2024 | Hdfc Bank Limited | ₹80.48 Lakh | Open |
| 13 May 2024 | Others | ₹5 Cr | Open |
Total charge records: 22 View all charges
Employees and EPFO Compliance at Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited has a workforce of 9 employees as of Mar 27, 2025.
Employee Count & EPFO Data of Sudarshan Pharma Industries Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Sudarshan Pharma Industries Limited
GSTIN & GST Filing Data of Sudarshan Pharma Industries Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Sudarshan Pharma Industries Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Sudarshan Pharma Industries Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Sudarshan Pharma Industries Limited
MSME Payment Delays by Sudarshan Pharma Industries Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Sudarshan Pharma Industries Limited
Subsidiaries & Group Companies of Sudarshan Pharma Industries Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Sudarshan Pharma Industries Limited with ownership details.
MCA Filings & Documents of Sudarshan Pharma Industries Limited
MCA Filings & Documents of Sudarshan Pharma Industries Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Sudarshan Pharma Industries Limited
Recent News on Sudarshan Pharma Industries Limited
Frequently Asked Questions about Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries Limited is an active public limited company in the professional services sector based in Mumbai, Maharashtra, India. It was incorporated on 23 July 2008 (18+ years old) and is registered under CIN L51496MH2008PLC184997. The company has 9 employees.
Sudarshan Pharma Industries Limited reported revenue of ₹507.57 Cr for FY 2025 (up 9.00% YoY).
The current directors of Sudarshan Pharma Industries Limited are:
- Jaya Ankur Singhania
- Vijay Ojha
- Rushabh Prashant Patil
- Hemal Vasantrai Mehta
- Sachin Vasantrai Mehta
- Nirav Kishor Shah
- Anil Balkrishna Ghogare
- Manoj Lalchand Lodha
- Nirav Kishor Shah
The primary industry of Sudarshan Pharma Industries Limited is professional services. The company specifically operates in scientific. The company is currently active in this sector.
Yes, Sudarshan Pharma Industries Limited is a listed company.
Sudarshan Pharma Industries Limited can be reached at the registered office: 301 3Rd Floor Aura Biplex Above Kalyan Jewellers S. V. Road Borivali West, Mumbai, Maharashtra, India – 400092, or through the website sudarshanpharma.com.